Raphael Pharmaceutical (RAPH) Share-based Compensation (2022 - 2025)
Raphael Pharmaceutical (RAPH) posted Share-based Compensation of $1000.0 for Q4 2025, down 97.44% sequentially from $39000.0 in Q3 2025, and down 99.65% YoY from $289000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Share-based Compensation (2022 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Share-based Compensation for 3 years, with the latest figure at $1000.0 in Q4 2025.
- Quarterly Share-based Compensation fell 99.65% year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $245000.0 (up 64.43% YoY) and the FY2025 annual result came in at $245000.0, down 30.0% from the prior year.
- Share-based Compensation slipped to $1000.0 in Q4 2025 per RAPH's latest filing, from $39000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $1.2 million in Q3 2022 and troughed at -$1.3 million in Q4 2022.
- A 3-year average of $76000.0 and a median of $140000.0 in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 99.65% in 2025, down 99.65% in 2025.
- Over 3 years, Share-based Compensation stood at -$1.3 million in 2022, then jumped by 121.57% to $289000.0 in 2024, then plunged by 99.65% to $1000.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1000.0, $39000.0, and $8000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2022 | -1.34 Mn |
| Dec 31, 2022 | -1.34 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 140,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Mar 31, 2022 | 150,000.00 |